09.29.21
SCHOTT has signed an agreement to acquire Applied Microarrays Inc., an Arizona-based microarray solutions company that extends SCHOTT’s manufacturing presence in the United States and strengthens its bioscience capabilities.
Customers will benefit from enhanced development and manufacturing capabilities in-cluding high-density microarray printing.
SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a close customer relation-ship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI will further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October.
Through this acquisition, SCHOTT MINIFAB significantly expands its biosensor printing capabilities. This is of particular importance as demand is growing for the manufacturing of point-of-care microarray consumables, especially in applications such as infectious disease detection.
“We pride ourselves on being an end-to-end partner for the global diagnostics industry. Our expansive offering allows us to provide an integrated single-source collection of value-intensive services and products. With the added bioscience knowledge of AMI, we become an even stronger partner, enhancing our capability in surface modification, functionalization and deposition for both glass and polymer products,” said Greg Wolters, head of SCHOTT MINIFAB.
AMI will soon be moving to a larger facility in the Phoenix, AZ area. Its new location will increase SCHOTT’s manufacturing footprint in the US to serve its global customer base.
Customers will benefit from enhanced development and manufacturing capabilities in-cluding high-density microarray printing.
SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a close customer relation-ship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI will further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October.
Through this acquisition, SCHOTT MINIFAB significantly expands its biosensor printing capabilities. This is of particular importance as demand is growing for the manufacturing of point-of-care microarray consumables, especially in applications such as infectious disease detection.
“We pride ourselves on being an end-to-end partner for the global diagnostics industry. Our expansive offering allows us to provide an integrated single-source collection of value-intensive services and products. With the added bioscience knowledge of AMI, we become an even stronger partner, enhancing our capability in surface modification, functionalization and deposition for both glass and polymer products,” said Greg Wolters, head of SCHOTT MINIFAB.
AMI will soon be moving to a larger facility in the Phoenix, AZ area. Its new location will increase SCHOTT’s manufacturing footprint in the US to serve its global customer base.
